Alumis Inc. (ALMS)

NASDAQ: ALMS · Real-Time Price · USD
4.390
-0.485 (-9.95%)
May 27, 2025, 3:28 PM - Market open
-9.95%
Market Cap 238.84M
Revenue (ttm) 17.39M
Net Income (ttm) -343.35M
Shares Out 54.41M
EPS (ttm) -8.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,060,405
Open 4.800
Previous Close 4.875
Day's Range 4.205 - 4.940
52-Week Range 3.180 - 13.530
Beta n/a
Analysts Strong Buy
Price Target 26.83 (+511.16%)
Earnings Date May 14, 2025

About ALMS

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company’s clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 28, 2024
Employees 170
Stock Exchange NASDAQ
Ticker Symbol ALMS
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ALMS stock is "Strong Buy." The 12-month stock price forecast is $26.83, which is an increase of 511.16% from the latest price.

Price Target
$26.83
(511.16% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Alumis Completes Merger with ACELYRIN

SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated...

6 days ago - GlobeNewsWire

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize cl...

12 days ago - GlobeNewsWire

Alumis Stockholders Approve Merger with ACELYRIN

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinica...

14 days ago - GlobeNewsWire

Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the...

5 weeks ago - GlobeNewsWire

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acelyrin, Inc. (...

Other symbols: SLRN
5 weeks ago - Business Wire

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

U.S. stocks were higher, with the Nasdaq Composite gaining over 200 points on Monday.

Other symbols: HTHOAMRNCCOECXHZONUTX
6 weeks ago - Benzinga

Top 3 Health Care Stocks That May Crash In Q2

As of April 7, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Other symbols: CMRXDERM
7 weeks ago - Benzinga

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote “FOR” the merger Transaction expected to be comple...

7 weeks ago - GlobeNewsWire

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

- Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and field option payments, plus tiered royalties...

2 months ago - GlobeNewsWire

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

– Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated;...

2 months ago - GlobeNewsWire

Alumis to Present at Leerink's 2025 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize ...

2 months ago - GlobeNewsWire

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

ESK-001 demonstrated robust clinical responses and was well tolerated over 52 weeks in a Phase 2 clinical trial, presented in a late-breaker at AAD 2025

2 months ago - GlobeNewsWire

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis”) and ACELYRIN, INC.

3 months ago - GlobeNewsWire

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma com...

Other symbols: SLRN
3 months ago - GlobeNewsWire

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

– Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension (OLE) study in adults with moderate-to-severe plaque psoriasis – – Additional Phase 2 e-poster ...

3 months ago - GlobeNewsWire

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis” or the “Company”), a clinical stage biopharmaceutical company developing oral therapies using a prec...

3 months ago - GlobeNewsWire

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize c...

3 months ago - GlobeNewsWire

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

NEW YORK , Feb. 7, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by ACELYRIN, INC. (NASDAQ: SLRN) and its board of directors concerning the proposed acquisi...

Other symbols: SLRN
3 months ago - PRNewsWire

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Company Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

3 months ago - GlobeNewsWire

Alumis Strengthens Leadership Team with Key Appointments

Jack Danilkowicz appointed as Chief Commercial Officer; bringing extensive experience successfully planning and executing commercial strategies at global biopharmaceutical companies  Sara Klein promot...

4 months ago - GlobeNewsWire

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

– Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to advance three clinical programs, ...

6 months ago - GlobeNewsWire

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

HC Wainwright has initiated coverage on Alumis Inc. ALMS, a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases.

Other symbols: BMY
7 months ago - Benzinga

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be the next immunology stock to soar on the Nasdaq? Investors who buy now can ge...

8 months ago - Seeking Alpha

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

28-week data show ESK-001 was generally well tolerated and most patients treated with the top dose of 40 mg twice daily achieved PASI 75 Three additional data presentations further support ESK-001's p...

8 months ago - GlobeNewsWire

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high ...

9 months ago - Seeking Alpha